Corporate | 19 June 2014 07:30
DGAP-News: Evotec AG / Key word(s): Miscellaneous
19.06.2014 / 07:30
---------------------------------------------------------------------
Hamburg, Germany - 19 June 2014: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX, ISIN: DE0005664809) today announced that its research alliance with
Boehringer Ingelheim has reached a milestone triggering a payment of EUR
1.0 m to Evotec. The milestone was for the transition of a back-up compound
from a respiratory programme into pre-clinical development.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We have
now achieved twenty three milestones as part of the collaboration with
Boehringer Ingelheim. The completed research phase of this alliance has led
to significant potential clinical milestones and royalties for compounds
that are already in pre-clinical and clinical development if they progress
successfully."
ABOUT THE EVOTEC & BOEHRINGER INGELHEIM ALLIANCE
In 2004, Evotec entered into a multi-year, multi-target drug discovery
alliance with Boehringer Ingelheim to jointly identify and develop
preclinical development candidates for the treatment of various disease
areas including CNS, inflammation, cardiometabolic and respiratory
diseases. In 2009, the collaboration was extended for an additional four
years and the scope expanded to include oncology targets. Under the terms
of the agreement, Boehringer Ingelheim has full ownership and global
responsibility for clinical development, manufacturing and
commercialisation of the compounds identified. In return, Evotec receives
ongoing research payments and pre-clinical milestones. Furthermore, the
contract provides substantial long-term upside for Evotec through potential
payments for successful milestone achievements during clinical development
and royalties when new drugs reach the market.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca,
Roche and UCB. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim,
MedImmune and Andromeda in the field of diabetes, with Janssen
Pharmaceuticals in the field of depression and with Roche in the field of
Alzheimer's disease. For additional information please go to
www.evotec.com.
FORWARD-LOOKING STATEMENTS: Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, gabriele.hansen@evotec.com
End of Corporate News
---------------------------------------------------------------------
19.06.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
274360 19.06.2014